DEA Considers Application for Controlled Substance Manufacturing

You might care about this because the Drug Enforcement Administration, also known as the DEA, has received an important application. American Radiolabeled Chem, a company based in Saint Louis, Missouri, wants to register as a bulk manufacturer of many controlled substances. This means they want to make these substances in large quantities. The company states that the purpose of this manufacturing is for biochemical research. They will use the substances as intermediate products or sell them to other customers for research. This notice is a formal step in the DEA's process to approve or deny such applications. It allows other registered manufacturers and applicants to submit comments or objections. Anyone wishing to comment or object must do so by September 21, 2026. The application includes a wide range of controlled substances. Some are Schedule I, like Gamma Hydroxybutyric Acid, Ibogaine, Lysergic acid diethylamide, Tetrahydrocannabinols, Dimethyltryptamine, 1-[1-(2-Thienyl)cyclohexyl]piperidine, Dihydromorphone, Heroin, and Normorphine. Others are Schedule II, such as Amphetamine, Methamphetamine, Amobarbital, Phencyclidine, Phenylacetone, Cocaine, Codeine, Dihydrocodeine, Oxycodone, Hydromorphone, Ecgonine, Hydrocodone, Meperidine, Metazocine, Methadone, Dextropropoxyphene, Morphine, Oripavine, Thebaine, Oxymorphone, Phenazocine, Carfentanil, and Fentanyl. The company specifically plans to make small amounts of these as radiolabeled compounds for research. For Tetrahydrocannabinols, they will produce it synthetically. The DEA notice clarifies that only these specific manufacturing activities are allowed under this potential registration. This document is interesting because it highlights how strictly the government monitors the production of even the most dangerous drugs, even for scientific purposes. Even when a company like American Radiolabeled Chem wants to work with substances like heroin, fentanyl, and LSD for research, the DEA requires a public application process. This process helps ensure that everything is transparent. It also gives others a chance to object if they have concerns. This system shows that producing these drugs, even for legitimate scientific research, is under heavy regulation. The fact that the company will make 'radiolabeled compounds' for 'biochemical research' points to advanced scientific work that still needs access to these substances. The document clearly states that only specific activities are allowed under this registration. This helps prevent any improper use and keeps tight control over these dangerous chemicals. It shows the careful balance the DEA must maintain. They support scientific discovery while also preventing controlled substances from being misused. This careful approach helps protect public health and safety. Several groups and professionals would be particularly interested in this legal document. Other companies that already manufacture controlled substances in bulk would want to review this notice. This includes other pharmaceutical and chemical companies that use these materials for research. Researchers and scientists in fields like biochemistry, pharmacology, and toxicology might find this relevant. They often need to know who is authorized to produce the specific research materials they use. Regulatory compliance officers within these industries would also pay close attention. They need to understand the DEA's rules and application process to ensure their own companies follow the law. Legal professionals who work with pharmaceutical law or regulatory affairs would also find this document important for their practice. Finally, members of the general public who are concerned about drug control and public safety might also want to understand how these substances are regulated, even when used for scientific purposes.